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Guidelines on the management of chronic obstructive pulmonary disease (COPD) issued by the European 
Respiratory Society (ERS), British Thoracic Society (BTS), American Thoracic Society (ATS), and Department of 
Health for England and Wales (DoH) suggest differing values of forced expiratory volume in 1 s (FEV,) below 
which arterial blood gas analysis should be performed to determine the presence of severe hypoxaemia and possible 
long-term oxygen therapy (LTOT) requirement. This study aimed to determine the value of FEV, at these different 
levels in screening for LTOT requirement defined as PaO, ~7.3 kPa in subjects with stable COPD. Comparative 
measures were taken against other lung function tests of volume and diffusing capacity. A retrospective analysis of 
paired lung function and arterial oxygen measurements in 491 subjects was made. The positive and negative 
predictive values, sensitivity and specificity of FEV, <70% predicted (ERS), FEV, ~50% predicted (ATS), FEV, 
~40% predicted (BTS) and FEV, < 1.5 1 (DoH) were determined for fulfilling LTOT criteria (PaO, ~7.3 kPa). The 
correlation between lung function variables and PaO, was established. Logistic regression analysis was used to 
classify subjects with PaO, ~7.3 kPa and PaO, > 7.3 kPa. 
Using FEV, to screen for LTOT requirement produced a high negative predictive value at all four suggested limits 
(FEV, ~70% lOO%, FEV, ~50% 96%, FEV, <40% 95%, FEV, cl.5 197%). However, the positive predictive values 
were low (FEV, ~70% 13%, FEV, ~50% 16%, FEV, <40% 19%, FEV, cl.5 1 15%) as were sensitivities. No single 
lung function variable was a strong determinant of PaO,. FEV, % pred (v=O.40), FVC % pred (v=O.34) and TLC0 
% pred (r=0.27) had the strongest relationships. Logistic regression also placed FEV, % pred and TLC0 % pred as 
the best predictors of PaO, ~7.3 kPa. We conclude no lung function variable correlates well with PaO, in subjects 
with stable COPD. The best predictor of PaO, c7.3 kPa was FEV, % pred. Whilst a low FEV, is a poor predictor 
of LTOT requirement in an individual, PaO, c7.3 kPa is only found in subjects with a low FEV,. A high FEV, may 
be used to exclude subjects from further investigation for LTOT and prevent unnecessary arterial sampling. 
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Introduction 
Domiciliary oxygen used for a minimum of 15 h day - I 
may extend the life expectancy of subjects with severe 
hypoxaemic chronic obstructive pulmonary disease 
(COPD) (1,Z): ‘The indications for prescription in the U.K. 
are based upon arterial blood gas values of PaO, ~7.3 kPa, 
although PaO, ~8 kPa in subjects with documented salt 
and water retention is a further indication in many centres. 
The Department of Health England and Wales (DoH) 
Drugs Tariff (3) recommends screening using spirometry 
followed by arterial blood gas analysis (ABG). This pro- 
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vides confirmation of airflow obstruction and may reduce 
the need for universal blood gas analysis. Spirometric 
values are also used to classify severity of COPD in 
the management guidelines issued by the American 
Thoracic Society (ATS) (4), European Respiratory 
Society (ERS) (5), and most recently the British Thoracic 
Society (BTS) (6). The need to consider oxygen therapy and 
hence arterial blood gas analysis is based upon spirometri- 
tally defined severity in these guidelines although different 
levels of FEV, are suggested in each document. The 
European guidelines specifically state that the relationship 
between spirometry and arterial oxygenation is poor but do 
not reference this and recommend oxygen therapy be 
considered in all cases of COPD. We determined to 
establish the relationship between FEV, and arterial 
oxygen levels in a large number of subjects with stable 
COPD and to assess the value of using the various 
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suggested screening levels of FEV, in identifying patients 
likely to benefit from LTOT. 
Subjects and Methods 
We retrospectively analysed the lung function data col- 
lected in the Department of Medicine at Charing Cross 
Hospital over a g-year period from 634 subjects with 
diagnostic coding for COPD. All subjects were coded for 
diagnosis by their referring doctor at the time of testing. A 
10% sample of cases was analysed to categorize the senior- 
ity of the referring doctor in order to validate the accuracy 
of the coding. Sixty-eight percent were of specialist consult- 
ant grade, 24% of registrar status and the remainder at 
more junior level. 
Details of hospital number, age, sex, height, weight, 
haemoglobin, and smoking history were retrieved from the 
hospital mainframe computer system. Lung function tests 
of spirometry, lung volumes determined by multibreath 
helium dilution, and diffusing capacity determined by single 
breath helium dilution and corrected for haemoglobin, were 
performed on all subjects and recorded as absolute values 
and as percent of their predicted mean values (% pred) (7). 
The lung function equipment used was either the PK 
Morgan Transfer Test Mark I (PK Morgan, Gillingham, 
U.K.) or the Gould CPI 5OOIV (Sensor Medics, 
Rugby, U.K.). Validation of the two separate systems 
has previously been made (8) and between-system repro- 
ducibility shown to be similar to that of intra-system 
reproducibility. 
Arterial blood gas samples were taken from the radial or 
brachial artery using a heparinized syringe by medical staff. 
Analysis was carried out using the Corning 168 pH/Blood 
gas analyser (Ciba Corning, Halstead) or the ABL300 
Acid-base Laboratory (Radiometer, Copenhagen). 
The data were then transferred to a PC and analysed 
using SPSSPC for Windows (SPSS inc. Chicago, U.S.A.). 
An initial data search was performed to eliminate transcrip- 
tion errors. Subjects with an FEV, >80% predicted or 
whose FEVi/FVC ratio was not reduced (i.e. >70% pre- 
dicted) were eliminated as not fulfilling the criteria for 
COPD, 92 subjects in all. This was to exclude smokers with 
symptoms but without significant airflow obstruction. 
Those who fulfilled the criteria but who had demonstrated 
> 15% reversibility on bronchodilator testing, 51 subjects, 
were also excluded from the study, i.e. asthmatic respond- 
ers. A further case note sample of 10% of the remaining 
subjects was examined to confirm the clinical diagnosis 
which was agreed as COPD in each case sampled. No 
subjects were tested when acutely unwell. 
Descriptive statistics were performed comprising mean, 
median, range and SD. The four FEV, screening criteria 
suggested by the DoH, ATS, ERS, and BTS, to assess for 
PaO, ~7.3 kPa were then applied to the subject group and 
their sensitivity, specificity, positive and negative predictive 
powers calculated. 
Correlation coefficients were then calculated for all 
the measured lung function variables with PaO, and 
scatterplots examined. 
Univariate logistic regression analysis applied to all the 
measured lung function variables was then used to classify 
subjects into two groups with PaO, values either below 
7.3 kPa or equal to or greater than 7.3 kPa. 
Results 
Of the original 634 subjects there were 491 who satisfied the 
criteria for COPD and who had complete data sets for 
analysis. There were 347 males. Ages ranged from 41 to 90 
years, mean 66.2 (9.2), height range 1.42 m-l.92 m, mean 
1.67 (0.09); and body mass index range 15.442-8, mean 
24.2 (4.7). Mean (SD) values and ranges for lung function 
data are given in Table 1. Fifty of the 491 subjects had a 
PaO, ~7.3 kPa. 
Sensitivity, specificity, positive and negative predictive 
values using the various FEV, screening criteria to selected 
subjects with PaO, ~7.3 kPa are shown in Table 2. 
Correlation coefficients for all lung function variables 
with PaO, expressed both in absolute measurements and as 
percent of predicted values (% pred) are shown in Table 3. 
The statistical significance of logistic regression analysis 
used for each individual lung function variable to classify 
subjects into those with PaO, greater than or equal to or 
less than 7.3 kPa are also given in the same table. The 
relative risk (RR) values describe the risk per unit value of 
the individual variable in classifying the study subjects 
correctly into the two groups PaO, less than 7.3 kPa or 
equal to or more than 7.3 kPa. Whilst none of the values 
have high correlation coefficients or logistic regression 
sensitivity, FEV, is shown to be superior to all the other 
parameters tested. 
The correlations between FEV, %pred with PaO, are 
shown as a scatterplot in Fig. 1. 
Discussion 
This study has defined the value and limitations of the use 
of the FEV, as a screening tool in the detection of severe 
hypoxaemia defined as a PaO, ~7.3 kPa, in a large number 
of subjects with stable COPD. An FEV, above the screen- 
ing levels suggested by the guidelines referenced has a high 
negative predictive value and in the absence of clinical signs 
suggesting otherwise virtually excludes severe hypoxaemia 
requiring LTOT. In contrast an FEV, below the 
suggested screening level has a poor predictive value for 
severe hypoxaemia and cannot be used to identify LTOT 
requirement (Table 2). 
The level of FEV, set to determine screening for ABG 
does affect the positive and negative predictive value of the 
test as well as the sensitivity and specificity. Raising the 
level of FEV, increases the negative predictive value but 
produces a reduction in the positive predictive value 
although all these changes were relatively small applied to 
the data set in this study (Table 2). The effect on sensitivity 
as applied to screening the COPD population is more 
marked (Table 2). Those using FEV, either as a determi- 
nant of severe hypoxia in an individual or in screening a 
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TABLE 1. Descriptive statistical data for lung function variables and anthropomorphic measures in 
491 subjects with stable COPD 
Mean STDDEV Minimum Maximum 
Age (years) 66.2 9.2 
Height (m) 1.66 0.09 
BMI 24.2 4.7 
FEV, (1) 1.10 0.51 
FEV, (% pred) (42.1) (15.9) 
FVC (1) 2.42 0.87 
FVC (% pred) (73.0) (19.0) 
FEF,, (1) 0.43 0.11 
RV (1) 3.41 0.98 
RV (% pred) (140.1) (54.5) 
TLC (1) 6.17 1.43 
TLC (1) (% pred) (97.2) (17.3) 
TLC0 (mm01 min - ’ kPa - ‘) 4.84 1.92 
TLC0 (% pred) (56.9) (21.9) 
TLCO/VA (mmol min - r kPa 11-l > 1.12 0.38 
TLCONA (% pred) (61.3) (24.9) 
PaO, (kPa) 9.19 1.44 
PaCO, (kPa) 5.55 0.82 
41 90 
1.43 1.89 
15.4 42.8 
0.20 2.75 
W) (79.5) 
0.45 5.46 
(12.3) (133.1) 
0.19 0.64 
1.18 6.84 
(59.0) (329.2) 
3.19 10.02 
(48.0) (161.3) 
0.68 12.88 
(11) (144) 
0.20 2.32 
(13) (142) 
5.57 12.97 
3.03 8.32 
population group must be aware of these effects when 
setting limits which should be adjusted according to the 
requirements of the user. 
There are limitations to this study. The findings presented 
here may not be universally applicable and should be used 
in similar population groups, i.e. stable COPD patients 
sufficiently compromised to warrant referral to hospital. 
Second, our analysis was retrospective and some sampling 
error is inevitable. The diagnostic code entered by the 
clinician at the time of testing cannot be verified in every 
case but a 10% sample of subjects revealed that 92% had 
been coded as COPD by medical staff with specialist 
respiratory training. Further attempts were made to elimi- 
nate miscoding errors by ensuring all subjects fulfilled 
spirometric criteria for COPD and excluding those with 
reversible airflow obstruction. The strength of the data base 
is in the large number of subjects studied which should 
minimize the impact of a small number of individual 
inaccuracies. 
When considering the relationship of lung function vari- 
ables with PaO, the measure of lung function that best 
TABLE 2. Sensitivity, specificity, positive and negative pre- 
dictive powers of the levels of FEV, recommended as 
screening tests for PaO, ~7-3 kPa 
FEV, Sensitivity Specificity PPV NPV 
cl.5 1 95% 23% 15% 97% 
<40% pred 80% 52% 19% 95% 
~50% pred 91% 32% 16% 96% 
~70% pred 100% 7% 13% 100% 
correlates with PaO, and predicts PaO, 17.3 kPa appears 
to be the FEV, % pred (r=0.40) which demonstrated mini- 
mal advantage over the FEV, expressed in absolute terms 
(v=O.39). It has a considerable advantage over all other 
measurements (Table 3). 
Correlations demonstrated for FEV, and FVC with 
arterial oxygen are similar to those recorded in previous 
studies of smaller numbers of subjects with COPD (9-13). 
Correlations were slightly improved using % predicted 
rather than absolute measures in our study. Although this 
might seem logical it contrasts with some previous smaller 
studies (9,10,12) where absolute terms had slightly better 
correlates than when expressed as % predicted, The differ- 
ences are not great however and the larger sample size of 
the current study may have produced a more significant 
statistical result on that basis alone. 
These findings of relatively low correlations and poor 
specificity are not too surprising interpreted in the light of 
the currently postulated mechanisms of hypoxia in COPD 
(alveolar hypoventilation, impaired alveolar-end capillary 
diffusion, increased vascular shunt, ventilation/perfusion 
(V/Q) mismatching, (14). Mismatching is thought to be the 
dominant factor in stable COPD (1417). Small airway 
obstruction and partial blockage of larger airways by 
mucous impaction contribute significantly to WQ inequal- 
ity. The FEV, is predominantly influenced by the large 
airways and may not accurately reflect important patho- 
physiological changes in the smaller airways. In addition 
the FEV, has no diagnostic ability to reflect abnormalities 
in pulmonary perfusion which may contribute to 
ventilation-perfusion mismatch. Alternative techniques 
such as pulse oximetry combined with lung function tests 
may improve the screening value but this method when 
considered alone also has significant limitations (18). 
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TABLE 3. Correlation coefficients for association between lung function variables expressed both in 
absolute measurements and percent of predicted mean values with measured PaO,. Relative risks 
(RR) and confidence intervals (CI) of logistic regression in classification of subjects into those with 
PaO, cl.3 kPa or 27.3 kPa 
Variable 
Correlation 
coefficient 
Logistic regression 
P 
(Spearman) Significance RR CI value 
Age (years) - 0.3 ns. 1.014 0.98, 1,048 n.s. 
FEV, (1) 0.39 <0~0001 6.380 2.58, 15.80 0~0001 
FEV, (% pred) 0.40 ~0~0001 1.058 1.03, 1.09 ~0~0001 
WC (1) 0.33 <0~0001 1.876 1.267, 2.778 0.0017 
FVC (% pred) 0.34 ~0~0001 1.030 1,011> 1.049 0.0016 
RV (1) - 0.07 n.s. 1.180 0.88, 1.58 n.s. 
RV (% pred) 0.01 us. 0,997 o-991, 1.003 n.s. 
TLC (1) 0.11 0.043 1,290 1.03, 1.60 0.0237 
TLC % pred 0.13 0.014 l-014 0.997, 1.032 n.s. 
TLC0 (mmol min - ’ kPa - ‘) 0.25 <0~0001 1,470 1.21, 1.78 0~0001 
TLC0 % pred 0.27 ~0~0001 1,041 1.022, 1.060 <O,OOOl 
TLCO/VA (mmol min - ’ kPa - ll-‘) 0.06 n.s. 2.350 1.07, 5.16 0.0327 
TLCONA % pred 0.09 n.s. 1.021 1.007, 1.035 0.0034 
100 
0’ ’ I I I I I I I I 
5 6 7 8 9 10 11 12 13 14 15 
PaO, (kPa) 
FIG. 1. Scattergram showing correlation of FEV, 
predicted with PaO,. 
Clinical signs of salt and water retention may also alert the 
clinician to the probability of car pulmonale in a subject 
with a low FEV,. 
In summary none of the measured lung function vari- 
ables are good predictors of severe hypoxaemia. FEV, is 
probably the best single test when expressed as % predicted 
and is easily performed. When applied to an individual with 
a value above those suggested for screening it has a high 
negative predictive power which should reduce referrals for 
unnecessary arterial sampling. Subjects with lower values of 
FEV, will still require arterial blood gas analysis. 
References 
1. Nocturnal Oxygen Therapy Trial Group. Continuous 
or nocturnal oxygen therapy in hypoxemic chronic 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
obstructive lung disease. A7279 Int Med 1980; 93: 391- 
398. 
Medical Research Council Working Party. Long term 
domiciliary oxygen therapy in chronic hypoxic car 
pulmonale complicating chronic bronchitis and 
emphysema. Lancet 1981; i: 683-685. 
Drugs Tariff. London: HMSO. 1996 App. X: 323-325. 
American Thoracic Society. Standards for the diag- 
nosis and care of patients with chronic obstructive 
pulmonary disease. Am J Crit Care Med 1995; 152 
(Suppl.): 77-120. 
European Respiratory Society. Optimal assessment and 
management of chronic obstructive pulmonary disease. 
Eur Respir J 1995; 8: 1398-1420. 
British Thoracic Society. Guidelines for the manage- 
ment of chronic obstructive pulmonary disease. Thorax 
1997; 52 (Suppl. 5): l-28. 
ERS Statement. Standardised lung function testing. 
Eur Respiv J 1993; 6 (Suppl. 16): l-100. 
Roberts CM, MacRae KD, Winning AJ, Adams L, 
Seed WA. Prediction equations for normal lung func- 
tion in a non-smoking Caucasian urban population. 
Thorax 1991; 46: 643-650. 
Palmer KNV, Diament ML. Relative contributions of 
obstructive and restrictive ventilatory impairment in 
the production of hypoxaemia and hypercapnia in 
chronic bronchitis. Lancet 1968; i: 1233-1234. 
Astin TW. Airways obstruction and arterial blood gas 
tensions in chronic obstructive pulmonary disease. 
Respiration 1972; 29: 74-82. 
Neukrich F, Castillon du Perron M, Verdier F et al. 
Etude stastitique des correlations entre les criteres 
spirographique et les presions partielles d’oxygene et 
d’anhydride carbonique dans le sang arteriel. Respir- 
ation 1975; 32: 165-178. 
1126 s. LIM ET AL 
12. 
13. 
14. 
15. 
Teculescu D, Manicatide M, Rocoveanu C. Ventilatory 
impairment and hypoxaemia in chronic non-specific 
lung disease. Bull Eur Physiopath Resp 1976; 12: 735- 
745. 
16. 
Delclaux B, Orcel B, Housset B, Whitelaw WA, 
Derenne J-P. Arterial blood gases in elderly persons 
with chronic obstructive pulmonary disease (COPD). 
Eur Respir J 1994; 7: 856-861. 
Agusti AG, Barbera JA. Contribution of multiple gas 
elimination technique to pulmonary medicine. 2. 
Chronic pulmonary diseases: chronic obstructive pul- 
monary disease and idiopathic pulmonary fibrosis. 
Thorax 1994; 49: 924932. 
Wagner PD, Dantzker DR, Dueck R, Clausen JL, 
West JB. Ventilation-perfusion inequality in chronic 
17. 
18. 
obstructive pulmonary disease. J Clin Invest 1977; 59: 
203-216. 
Dantzker DR. Gas exchange. In: Montenegro HD, ed. 
Chronic Obstructive Pulmonary Disease. Edinburgh: 
Churchill Livingstone, 1994: 141-160. 
Rodriguez-Roisin R, Rota J. Pulmonary gas exchange. 
In: Calverley P, Pride N, eds. Chronic Obstructive 
Pulmonary Disease. London: Chapman and Hall, 1995: 
161-184. 
Roberts CM, Bugler RJ, Melchor R, Hetzel MR, Spiro 
SG. Value of pulse oximetry in screening for long term 
oxygen therapy requirement. Eur Respir J 1993; 6: 
5599562. 
